Clinical Trials Directory

Trials / Completed

CompletedNCT02295124

Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
200 (actual)
Sponsor
University Health Network, Toronto · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The study aims to compare the incidence of side effects caused by Oxycodone and Hydromorphone.

Detailed description

Nausea and vomiting in the post-operative period is considered strongly undesirable by patients and has adverse effects on recovery from outpatient procedures, contributing significantly to delays in discharge from recovery. A know major contributor to the occurrence of post-operative nausea and vomiting is the use of opiate medications which are the cornerstone of post-operative pain management. The investigators hypothesize that the occurrence of this side-effect is different between patients prescribed oxycodone and those receiving hydromorphone for acute pain management after total hip replacement surgery. This investigation is a randomized, double-blind, head-to-head comparison to equipotent administration of oxycodone vs. hydromorphone to determine whether such a difference exists.

Conditions

Interventions

TypeNameDescription
DRUGOxycodonePatients will receive oxycodone 10mg (5mg if \> 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
DRUGHydromorphonePatients will receive an initial dose of hydromorphone 2mg (1mg if \> 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.

Timeline

Start date
2012-08-01
Primary completion
2016-01-01
Completion
2016-01-01
First posted
2014-11-20
Last updated
2017-11-27

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02295124. Inclusion in this directory is not an endorsement.